The probiotic Lactobacillus rhamnosus for alleviation of helicobacter pylori-associated gastric pathology in East Africa

Nieke Westerik, Gregor Reid, Wilbert Sybesma, Remco Kort

Research output: Contribution to JournalReview articleAcademicpeer-review

Abstract

The probiotic Lactobacillus rhamnosus GG (LGG) can play a role in establishing a harmless relationship with Helicobacter pylori and reduce gastric pathology in East African populations. H. pylori has the ability to inhabit the surface of the mucous layer of the human stomach and duodenum. In the developing world, an estimated 51% of the population is carrier of H. pylori, while in some Western countries these numbers dropped below 20%, which is probably associated with improved sanitation and smaller family sizes. Colonization by H. pylori can be followed by inflammation of the gastric mucus layer, and is a risk factor in the development of atrophic gastritis, peptic ulcers and gastric cancer. Notwithstanding the higher prevalence of H. pylori carriers in developing countries, no equal overall increase in gastric pathology is found. This has been attributed to a less pro-inflammatory immune response to H. pylori in African compared to Caucasian populations. In addition, a relatively low exposure to other risk factors in certain African populations may play a role, including the use of non-steroidal anti-inflammatory drugs, smoking, and diets without certain protective factors. A novel approach to the reduction of H. pylori associated gastric pathology is found in the administration of the probiotic bacterium Lactobacillus rhamnosus yoba 2012 (LRY), the generic variant of LGG. This gastro-intestinal isolate inhibits H. pylori by competition for substrate and binding sites as well as production of antimicrobial compounds such as lactic acid. In addition, it attenuates the host's H. pylori-induced apoptosis and inflammation responses and stimulates angiogenesis in the gastric and duodenal epithelium. The probiotic LRY is not able to eradicate H. pylori completely, but its co-supplementation in antibiotic eradication therapy has been shown to relieve side effects of this therapy. In Uganda, unlike other African countries, gastric pathology is relatively common, presumably resulting from the lack of dietary protective factors in the traditional diet. Supplementation with LRY through local production of probiotic yogurt, could be a solution to establish a harmless relationship with H. pylori and reduce gastric pathology and subsequent eradication therapy treatment.

Original languageEnglish
Article number1873
Pages (from-to)1-13
Number of pages13
JournalFrontiers in Microbiology
Volume9
Issue numberAUGUST
DOIs
Publication statusPublished - 14 Aug 2018

Fingerprint

Lactobacillus rhamnosus
Eastern Africa
Probiotics
Helicobacter pylori
Stomach
Pathology
Population
Diet
Inflammation
Atrophic Gastritis
Yogurt
Aptitude
Sanitation
Uganda
Mucus
Peptic Ulcer
Duodenum
Developing Countries
Stomach Neoplasms
Lactic Acid

Keywords

  • East Africa
  • Eradication therapy
  • Gastric pathology
  • Helicobacter pylori
  • Lactobacillus rhamnosus GG
  • Lactobacillus rhamnosus yoba 2012
  • Uganda
  • Ulcer

Cite this

@article{49a867ade2b24349bd52d4c49074ae19,
title = "The probiotic Lactobacillus rhamnosus for alleviation of helicobacter pylori-associated gastric pathology in East Africa",
abstract = "The probiotic Lactobacillus rhamnosus GG (LGG) can play a role in establishing a harmless relationship with Helicobacter pylori and reduce gastric pathology in East African populations. H. pylori has the ability to inhabit the surface of the mucous layer of the human stomach and duodenum. In the developing world, an estimated 51{\%} of the population is carrier of H. pylori, while in some Western countries these numbers dropped below 20{\%}, which is probably associated with improved sanitation and smaller family sizes. Colonization by H. pylori can be followed by inflammation of the gastric mucus layer, and is a risk factor in the development of atrophic gastritis, peptic ulcers and gastric cancer. Notwithstanding the higher prevalence of H. pylori carriers in developing countries, no equal overall increase in gastric pathology is found. This has been attributed to a less pro-inflammatory immune response to H. pylori in African compared to Caucasian populations. In addition, a relatively low exposure to other risk factors in certain African populations may play a role, including the use of non-steroidal anti-inflammatory drugs, smoking, and diets without certain protective factors. A novel approach to the reduction of H. pylori associated gastric pathology is found in the administration of the probiotic bacterium Lactobacillus rhamnosus yoba 2012 (LRY), the generic variant of LGG. This gastro-intestinal isolate inhibits H. pylori by competition for substrate and binding sites as well as production of antimicrobial compounds such as lactic acid. In addition, it attenuates the host's H. pylori-induced apoptosis and inflammation responses and stimulates angiogenesis in the gastric and duodenal epithelium. The probiotic LRY is not able to eradicate H. pylori completely, but its co-supplementation in antibiotic eradication therapy has been shown to relieve side effects of this therapy. In Uganda, unlike other African countries, gastric pathology is relatively common, presumably resulting from the lack of dietary protective factors in the traditional diet. Supplementation with LRY through local production of probiotic yogurt, could be a solution to establish a harmless relationship with H. pylori and reduce gastric pathology and subsequent eradication therapy treatment.",
keywords = "East Africa, Eradication therapy, Gastric pathology, Helicobacter pylori, Lactobacillus rhamnosus GG, Lactobacillus rhamnosus yoba 2012, Uganda, Ulcer",
author = "Nieke Westerik and Gregor Reid and Wilbert Sybesma and Remco Kort",
year = "2018",
month = "8",
day = "14",
doi = "10.3389/fmicb.2018.01873",
language = "English",
volume = "9",
pages = "1--13",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S.A.",
number = "AUGUST",

}

The probiotic Lactobacillus rhamnosus for alleviation of helicobacter pylori-associated gastric pathology in East Africa. / Westerik, Nieke; Reid, Gregor; Sybesma, Wilbert; Kort, Remco.

In: Frontiers in Microbiology, Vol. 9, No. AUGUST, 1873, 14.08.2018, p. 1-13.

Research output: Contribution to JournalReview articleAcademicpeer-review

TY - JOUR

T1 - The probiotic Lactobacillus rhamnosus for alleviation of helicobacter pylori-associated gastric pathology in East Africa

AU - Westerik, Nieke

AU - Reid, Gregor

AU - Sybesma, Wilbert

AU - Kort, Remco

PY - 2018/8/14

Y1 - 2018/8/14

N2 - The probiotic Lactobacillus rhamnosus GG (LGG) can play a role in establishing a harmless relationship with Helicobacter pylori and reduce gastric pathology in East African populations. H. pylori has the ability to inhabit the surface of the mucous layer of the human stomach and duodenum. In the developing world, an estimated 51% of the population is carrier of H. pylori, while in some Western countries these numbers dropped below 20%, which is probably associated with improved sanitation and smaller family sizes. Colonization by H. pylori can be followed by inflammation of the gastric mucus layer, and is a risk factor in the development of atrophic gastritis, peptic ulcers and gastric cancer. Notwithstanding the higher prevalence of H. pylori carriers in developing countries, no equal overall increase in gastric pathology is found. This has been attributed to a less pro-inflammatory immune response to H. pylori in African compared to Caucasian populations. In addition, a relatively low exposure to other risk factors in certain African populations may play a role, including the use of non-steroidal anti-inflammatory drugs, smoking, and diets without certain protective factors. A novel approach to the reduction of H. pylori associated gastric pathology is found in the administration of the probiotic bacterium Lactobacillus rhamnosus yoba 2012 (LRY), the generic variant of LGG. This gastro-intestinal isolate inhibits H. pylori by competition for substrate and binding sites as well as production of antimicrobial compounds such as lactic acid. In addition, it attenuates the host's H. pylori-induced apoptosis and inflammation responses and stimulates angiogenesis in the gastric and duodenal epithelium. The probiotic LRY is not able to eradicate H. pylori completely, but its co-supplementation in antibiotic eradication therapy has been shown to relieve side effects of this therapy. In Uganda, unlike other African countries, gastric pathology is relatively common, presumably resulting from the lack of dietary protective factors in the traditional diet. Supplementation with LRY through local production of probiotic yogurt, could be a solution to establish a harmless relationship with H. pylori and reduce gastric pathology and subsequent eradication therapy treatment.

AB - The probiotic Lactobacillus rhamnosus GG (LGG) can play a role in establishing a harmless relationship with Helicobacter pylori and reduce gastric pathology in East African populations. H. pylori has the ability to inhabit the surface of the mucous layer of the human stomach and duodenum. In the developing world, an estimated 51% of the population is carrier of H. pylori, while in some Western countries these numbers dropped below 20%, which is probably associated with improved sanitation and smaller family sizes. Colonization by H. pylori can be followed by inflammation of the gastric mucus layer, and is a risk factor in the development of atrophic gastritis, peptic ulcers and gastric cancer. Notwithstanding the higher prevalence of H. pylori carriers in developing countries, no equal overall increase in gastric pathology is found. This has been attributed to a less pro-inflammatory immune response to H. pylori in African compared to Caucasian populations. In addition, a relatively low exposure to other risk factors in certain African populations may play a role, including the use of non-steroidal anti-inflammatory drugs, smoking, and diets without certain protective factors. A novel approach to the reduction of H. pylori associated gastric pathology is found in the administration of the probiotic bacterium Lactobacillus rhamnosus yoba 2012 (LRY), the generic variant of LGG. This gastro-intestinal isolate inhibits H. pylori by competition for substrate and binding sites as well as production of antimicrobial compounds such as lactic acid. In addition, it attenuates the host's H. pylori-induced apoptosis and inflammation responses and stimulates angiogenesis in the gastric and duodenal epithelium. The probiotic LRY is not able to eradicate H. pylori completely, but its co-supplementation in antibiotic eradication therapy has been shown to relieve side effects of this therapy. In Uganda, unlike other African countries, gastric pathology is relatively common, presumably resulting from the lack of dietary protective factors in the traditional diet. Supplementation with LRY through local production of probiotic yogurt, could be a solution to establish a harmless relationship with H. pylori and reduce gastric pathology and subsequent eradication therapy treatment.

KW - East Africa

KW - Eradication therapy

KW - Gastric pathology

KW - Helicobacter pylori

KW - Lactobacillus rhamnosus GG

KW - Lactobacillus rhamnosus yoba 2012

KW - Uganda

KW - Ulcer

UR - http://www.scopus.com/inward/record.url?scp=85051460702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051460702&partnerID=8YFLogxK

U2 - 10.3389/fmicb.2018.01873

DO - 10.3389/fmicb.2018.01873

M3 - Review article

VL - 9

SP - 1

EP - 13

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - AUGUST

M1 - 1873

ER -